Foreign-Trade Zone (FTZ) 99-Wilmington, Delaware, Notification of Proposed Production Activity AstraZeneca Pharmaceuticals, LP (Pharmaceutical Products), Newark, Delaware, 10771 [2022-03953]

Download as PDF lotter on DSK11XQN23PROD with NOTICES1 Federal Register / Vol. 87, No. 38 / Friday, February 25, 2022 / Notices representative samples using transparent methodology. The BTOS will produce data continuously, in part as a response to feedback on the SBPS that longer time series would have been useful to contextualize the pandemic impact. Continuous data will allow for the measurement of economic trends during all phases of the business cycle as well as during times of economic and other emergencies. The BTOS will uniquely provide the ability to produce these data and associated measures of quality. The BTOS data series will provide insight on the state of the economy, prior to and during an event (including but not limited to natural disasters or economic crises) and will assist in monitoring the recovery from the event. It will also be useful in understanding aggregate and subaggregate changes in economic trends throughout the business cycle. BTOS data may be used by elected officials, government program officials, policy makers, industry leaders, economic and social analysts, business entrepreneurs, business and economic news organizations, and domestic and foreign researchers in academia, business, and government. The BTOS will allow for a large number of data products that are complementary to the Census Bureau’s existing monthly and quarterly economic indicator programs which provide estimates of contemporaneous economic activity at the national sector level. The BTOS will produce complementary disaggregate contemporaneous data as well as data that reflect the outlook of businesses. The BTOS will be complementary to the Census Bureau’s existing annual programs, serving as a platform through which trends and data gaps may first be identified for subsequent inclusion in annual programs. The BTOS instrument will include core and supplemental content. Core content will form the basis of the instrument and run continuously; core content will include measures of economic activity that are applicable across all non-farm sectors and are important across the business cycle and during economic or other emergencies. Supplemental content will be included on the instrument with a regular periodicity and will be designed to provide urgently needed data on an emerging or current issue. Core concepts for the BTOS will be selected based on research and analysis conducted during the SBPS, stakeholder feedback, and the ability to collect complementary items on monthly, VerDate Sep<11>2014 16:44 Feb 24, 2022 Jkt 256001 quarterly, annual, or census programs to provide context and benchmarking. Initially, all data products will be accessible through the Census Bureau’s Experimental Data Products site. Experimental data products are clearly identified and include methodology and supporting research with their release. Affected Public: Business or other forprofit organizations. Frequency: Bi-weekly. Respondent’s Obligation: Voluntary. Legal Authority: Title 13 U.S.C., Sections 131 and 182. This information collection request may be viewed at www.reginfo.gov. Follow the instructions to view the Department of Commerce collections currently under review by OMB. Written comments and recommendations for the proposed information collection should be submitted within 30 days of the publication of this notice on the following website www.reginfo.gov/ public/do/PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function and entering the title of the collection. Sheleen Dumas, Department PRA Clearance Officer, Office of the Chief Information Officer, Commerce Department. [FR Doc. 2022–04060 Filed 2–24–22; 8:45 am] BILLING CODE 3510–07–P DEPARTMENT OF COMMERCE Foreign-Trade Zones Board [B–05–2022] Foreign-Trade Zone (FTZ) 99— Wilmington, Delaware, Notification of Proposed Production Activity AstraZeneca Pharmaceuticals, LP (Pharmaceutical Products), Newark, Delaware AstraZeneca Pharmaceuticals, LP submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Newark, Delaware within Subzone 99D. The notification conforming to the requirements of the Board’s regulations (15 CFR 400.22) was received on February 16, 2022. Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status materials and specific finished products described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity PO 00000 Frm 00008 Fmt 4703 Sfmt 4703 10771 under FTZ procedures are explained in the background section of the Board’s website—accessible via www.trade.gov/ ftz. The proposed finished products and materials would be added to the production authority that the Board previously approved for the operation, as reflected on the Board’s website. The proposed finished products include: BRILINTA (ticagrelor) tablets; LYNPARZA (olaparib) tablets; SEROQUEL IR (quetiapine fumarate) tablets; and, SEROQUEL XR (quetiapine fumarate) tablets (duty-free). The proposed foreign-status materials include: Anastrozole active pharmaceutical ingredient (API); olaparib API; quetiapine fumarate API; and, ticagrelor API (duty rates 6.5%). The request indicates that olaparib API and ticagrelor API are subject to duties under Section 301 of the Trade Act of 1974 (Section 301), depending on the country of origin. The applicable Section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41). Public comment is invited from interested parties. Submissions shall be addressed to the Board’s Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is April 6, 2022. A copy of the notification will be available for public inspection in the ‘‘Online FTZ Information System’’ section of the Board’s website. For further information, contact Christopher Wedderburn at Chris.Wedderburn@trade.gov. Dated: February 18, 2022. Andrew McGilvray, Executive Secretary. [FR Doc. 2022–03953 Filed 2–24–22; 8:45 am] BILLING CODE 3510–DS–P DEPARTMENT OF COMMERCE Bureau of Industry and Security Transportation and Related Equipment Technical Advisory Committee; Notice of Partially Closed Meeting The Transportation and Related Equipment Technical Advisory Committee will meet on March 16, 2022, at 11:30 a.m., Eastern Standard Time, via teleconference. The Committee advises the Office of the Assistant Secretary for Export Administration with respect to technical questions that affect the level of export controls applicable to transportation and related equipment or technology. E:\FR\FM\25FEN1.SGM 25FEN1

Agencies

[Federal Register Volume 87, Number 38 (Friday, February 25, 2022)]
[Notices]
[Page 10771]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03953]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-05-2022]


Foreign-Trade Zone (FTZ) 99--Wilmington, Delaware, Notification 
of Proposed Production Activity AstraZeneca Pharmaceuticals, LP 
(Pharmaceutical Products), Newark, Delaware

    AstraZeneca Pharmaceuticals, LP submitted a notification of 
proposed production activity to the FTZ Board (the Board) for its 
facility in Newark, Delaware within Subzone 99D. The notification 
conforming to the requirements of the Board's regulations (15 CFR 
400.22) was received on February 16, 2022.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status materials and specific finished 
products described in the submitted notification (summarized below) and 
subsequently authorized by the Board. The benefits that may stem from 
conducting production activity under FTZ procedures are explained in 
the background section of the Board's website--accessible via 
www.trade.gov/ftz. The proposed finished products and materials would 
be added to the production authority that the Board previously approved 
for the operation, as reflected on the Board's website.
    The proposed finished products include: BRILINTA (ticagrelor) 
tablets; LYNPARZA (olaparib) tablets; SEROQUEL IR (quetiapine fumarate) 
tablets; and, SEROQUEL XR (quetiapine fumarate) tablets (duty-free).
    The proposed foreign-status materials include: Anastrozole active 
pharmaceutical ingredient (API); olaparib API; quetiapine fumarate API; 
and, ticagrelor API (duty rates 6.5%). The request indicates that 
olaparib API and ticagrelor API are subject to duties under Section 301 
of the Trade Act of 1974 (Section 301), depending on the country of 
origin. The applicable Section 301 decisions require subject 
merchandise to be admitted to FTZs in privileged foreign status (19 CFR 
146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is April 6, 2022.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Christopher Wedderburn at 
[email protected].

    Dated: February 18, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-03953 Filed 2-24-22; 8:45 am]
BILLING CODE 3510-DS-P